SCHEMBL6367231

SCHEMBL6367231

CC1CN(c2ccc(Cl)cc2)CC(C)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
ADRB1 P08588 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
MAPK13 O15264 1/20 0.46
MAPK12 P53778 1/20 0.46
MAPK11 Q15759 1/20 0.46
MAPK14 Q16539 1/20 0.46
KMT2A Q03164 1/20 0.44
HTT P42858 1/20 0.42
NOTUM Q6P988 1/20 0.41
GHSR Q92847 5/20 0.40
TGFBR1 P36897 1/20 0.40
ACVR1 Q04771 1/20 0.40
KCNH2 Q12809 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6367230 1.00 HTR3E (0.47) HTR3EHTR3BADRB1HTR3AHTR3D
Hydrochloric Acid SCHEMBL6650717 0.98 HTR3E (0.46) HTR3EHTR3BADRB1HTR3AHTR3D
Hydrochloric Acid SCHEMBL6367409 0.98 HTR3E (0.46) HTR3EHTR3BADRB1HTR3AHTR3D
SCHEMBL81695 0.82 ADRB1 (0.48) ADRB1KMT2AHTTGHSRTGFBR1
SCHEMBL81349 0.82 ADRB1 (0.48) ADRB1KMT2AHTTGHSRTGFBR1
SCHEMBL19570980 0.81 HTR3E (0.47) HTR3EHTR3BADRB1HTR3AHTR3D
SCHEMBL13239751 0.81 L3MBTL1 (0.45) KMT2AHTTNOTUMGHSRTGFBR1
SCHEMBL16069835 0.80 MAPT (0.47) SIGMAR1KMT2AHTTGHSRTGFBR1
SCHEMBL3528425 0.80 MAPT (0.47) SIGMAR1KMT2AHTTGHSRTGFBR1
SCHEMBL578246 0.80 GHSR (0.53) SIGMAR1KMT2AHTTGHSRTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080096-A1 Condensed heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-04-14 US disclosed
EP-1469854-A1 CONDENSED HETEROCYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-27 EP disclosed
WO-2003063874-A1 CONDENSED HETEROCYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080096-A1 Condensed heterocyclic compounds PARP1, PARP2, PARP3 HTR3E 758/4885HTR3B 645/4885ADRB1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.